Anti-BRCA1 antibody [GLK-2] (ab17251)

Overview

  • Product nameAnti-BRCA1 antibody [GLK-2]
    See all BRCA1 primary antibodies
  • Description
    Mouse monoclonal [GLK-2] to BRCA1
  • Tested applicationsSuitable for: IHC-Pmore details
    Unsuitable for: ICC/IF
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Cow, Dog, Chimpanzee, Rhesus monkey, Gorilla
  • Immunogen

    Synthetic peptide:

    LDSVALYQCQELDTYLIPQIPHSHY

    , corresponding to C terminal amino acids 1839-1863 of Human BRCA1.

  • Positive control
    • Ovarian carcinoma
  • General notes


    ab17251 stains 94% of ovarian carcinomas with a mutation in exon 11. However, staining is absent in 100% of tumors with mutations other than exon 11.

Properties

Applications

Our Abpromise guarantee covers the use of ab17251 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/15 - 1/50. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

1/15 - 1/50 in an ABC method. An incubation period of 30-60 minutes at room temperature is recommended. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining.

  • Application notesIs unsuitable for ICC/IF.
  • Target

    • FunctionE3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
    • Tissue specificityIsoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
    • PathwayProtein modification; protein ubiquitination.
    • Involvement in diseaseDefects in BRCA1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.
      Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.
      Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705].
    • Sequence similaritiesContains 2 BRCT domains.
      Contains 1 RING-type zinc finger.
    • DomainThe BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites.
      The RING-type zinc finger domain interacts with BAP1.
    • Post-translational
      modifications
      Phosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
      Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation.
    • Cellular localizationCytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.
    • Information by UniProt
    • Database links
    • Alternative names
      • BRCA 1 antibody
      • BRCA1 antibody
      • BRCA1/BRCA2 containing complex subunit 1 antibody
      • BRCA1/BRCA2-containing complex, subunit 1 antibody
      • BRCA1_HUMAN antibody
      • BRCAI antibody
      • BRCC 1 antibody
      • BRCC1 antibody
      • Breast and ovarian cancer susceptibility protein 1 antibody
      • Breast Cancer 1 antibody
      • Breast Cancer 1 Early Onset antibody
      • Breast cancer type 1 susceptibility protein antibody
      • BROVCA1 antibody
      • IRIS antibody
      • PNCA4 antibody
      • PPP1R53 antibody
      • Protein phosphatase 1 regulatory subunit 53 antibody
      • PSCP antibody
      • RING finger protein 53 antibody
      • RNF53 antibody
      see all

    References for Anti-BRCA1 antibody [GLK-2] (ab17251)

    ab17251 has not yet been referenced specifically in any publications.

    Product Wall

    Application Immunocytochemistry
    Sample Human Cultured Cells (MCF-7,HCC3153,UWB1.289)
    Permeabilization Yes - Methanol
    Specification MCF-7,HCC3153,UWB1.289
    Blocking step VECTASTAIN Elite ABC Kit (Vector laboratories) ) as blocking agent for 30 minute(s) · Concentration: 100%
    Fixative Formaldehyde
    Username

    Prof. Sophie Doisneau-Sixou

    Verified customer

    Submitted Oct 17 2015

    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (MCF-7,HCC3153,UWB1.289)
    Permeabilization Yes - Methanol
    Specification MCF-7,HCC3153,UWB1.289
    Blocking step (agent) for 15 minute(s) · Concentration: 100% · Temperature: RT°C
    Fixative Formaldehyde
    Username

    Prof. Sophie Doisneau-Sixou

    Verified customer

    Submitted Oct 16 2015

    Abcam has not validated the combination of species/application used in this Abreview.
    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (HeLa and SK-N-SH)
    Specification HeLa and SK-N-SH
    Fixative Paraformaldehyde
    Username

    Dr. Kirk McManus

    Verified customer

    Submitted Nov 30 2006

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"